David A. Siegel Ptc Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 429,842 shares of PTCT stock, worth $18.5 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

429,842

Previous 389,542 10.35%

Holding current value

$18.5 Million

Previous $11.9 Million 33.87%

% of portfolio

0.04%

Previous 0.03%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$30.39 - $37.66 $1.22 Million - $1.52 Million	40,300 Added 10.35%	429,842 $15.9 Million
Q2 2024 Aug 14, 2024	SELL	$24.69 - $40.12 $91,353 - $148,444	-3,700 Reduced 0.94%	389,542 $11.9 Million
Q1 2024 May 15, 2024	BUY	$24.15 - $31.95 $4.91 Million - $6.5 Million	203,400 Added 107.14%	393,242 $11.4 Million
Q4 2023 Feb 14, 2024	SELL	$18.07 - $29.37 $258,401 - $419,991	-14,300 Reduced 7.0%	189,842 $5.23 Million
Q3 2023 Nov 14, 2023	SELL	$22.41 - $41.99 $1.84 Million - $3.46 Million	-82,300 Reduced 28.73%	204,142 $4.57 Million
Q2 2023 Aug 14, 2023	SELL	$40.4 - $59.1 $1.7 Million - $2.49 Million	-42,200 Reduced 12.84%	286,442 $11.6 Million
Q1 2023 May 15, 2023	BUY	$38.16 - $48.86 $370,151 - $473,942	9,700 Added 3.04%	328,642 $15.9 Million
Q4 2022 Feb 14, 2023	BUY	$33.53 - $54.79 $1.54 Million - $2.51 Million	45,900 Added 16.81%	318,942 $12.2 Million
Q3 2022 Nov 14, 2022	BUY	$41.85 - $53.85 $11.4 Million - $14.7 Million	273,042 New	273,042 $13.7 Million
Q3 2022 Nov 14, 2022	BUY	$41.85 - $53.85 $11.4 Million - $14.7 Million	273,042 New	273,042 $13.7 Million
Q1 2022 May 16, 2022	SELL	$33.33 - $44.6 $183,315 - $245,300	-5,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.36 - $41.86 $194,480 - $230,230	5,500 New	5,500 $219,000
Q1 2021 May 17, 2021	SELL	$46.8 - $68.92 $327,600 - $482,440	-7,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$47.96 - $67.64 $1.99 Million - $2.8 Million	-41,400 Reduced 85.54%	7,000 $427,000
Q3 2020 Nov 16, 2020	SELL	$45.41 - $57.07 $9.71 Million - $12.2 Million	-213,842 Reduced 81.54%	48,400 $2.26 Million
Q2 2020 Aug 14, 2020	SELL	$42.56 - $54.98 $1.87 Million - $2.41 Million	-43,900 Reduced 14.34%	262,242 $13.3 Million
Q1 2020 May 15, 2020	BUY	$32.37 - $59.36 $1.34 Million - $2.46 Million	41,400 Added 15.64%	306,142 $13.7 Million
Q4 2019 Feb 14, 2020	BUY	$32.22 - $50.07 $8.53 Million - $13.3 Million	264,742 New	264,742 $12.7 Million
Q3 2019 Nov 14, 2019	SELL	$33.82 - $48.17 $253,650 - $361,275	-7,500 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$35.42 - $45.0 $1.71 Million - $2.17 Million	-48,300 Reduced 86.56%	7,500 $338,000
Q1 2019 May 15, 2019	SELL	$28.09 - $39.49 $317,417 - $446,237	-11,300 Reduced 16.84%	55,800 $2.1 Million
Q4 2018 Feb 14, 2019	SELL	$29.83 - $46.51 $3 Million - $4.68 Million	-100,600 Reduced 59.99%	67,100 $2.3 Million
Q3 2018 Nov 14, 2018	SELL	$33.9 - $47.77 $7.54 Million - $10.6 Million	-222,500 Reduced 57.02%	167,700 $7.88 Million
Q2 2018 Aug 14, 2018	BUY	$25.7 - $47.88 $1.3 Million - $2.42 Million	50,600 Added 14.9%	390,200 $13.2 Million
Q1 2018 May 15, 2018	BUY	$17.46 - $32.59 $5.93 Million - $11.1 Million	339,600 New	339,600 $9.19 Million

Others Institutions Holding PTCT

# of Institutions

222

Shares Held

78.1M

Call Options Held

144K

Put Options Held

58.7K

View Full List

About PTC THERAPEUTICS, INC.

Ticker PTCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,541,000
Market Cap $3.08B
Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...

More about PTCT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account